Effectiveness and Safety of Tigecycline Combined with Cefoperazone-sulbactam Sodium in the Treatment of Multi-/extensively-drug Resistant Acinetobacter baumannii-associated Central Nervous System Infection:A Meta-analysis
10.3870/j.issn.1004-0781.2024.01.021
- VernacularTitle:替加环素联合头孢哌酮/舒巴坦钠治疗多重/泛耐药鲍曼不动杆菌中枢神经系统感染有效性及安全性的Meta分析
- Author:
Taojunjin LU
1
;
Mingjuan ZHAO
;
Wei WANG
;
Zhiyong PAN
;
Qin HU
;
Yirong LI
;
Zhiqiang LI
Author Information
1. 武汉大学中南医院 神经外科,武汉 430071
- Keywords:
Tigecycline;
Cefoperazone-sulbactam sodium;
Multi-/extensively-drug resistant Acinetobacter baumannii;
Central nervous system infection;
Meta-analysis
- From:
Herald of Medicine
2024;43(1):131-136
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of tigecycline combined with cefoperazone-sulbactam sodium in the treatment of multi-/extensively-drug resistant Acinetobacter baumannii(MDRAB/XDRAB)associated central nervous system(CNS)infection,and to provide clinical evidence for antibiotic treatment of MDRAB/XDRAB-related intracranial disease.Methods The Wanfang Data Knowledge Service Platform,Chinese Biomedical Literature Database,VIP Chinese Science and Technology Journal Full-text Database,China National Knowledge Infrastructure(CNKI),Pubmed,Embase database,and Cochrane Library were searched to extract the literature of randomized controlled studies on tigecycline and cefoperazone sulbactam in the treatment of MDRAB/XDRAB CNS infection until September 1st,2022.The included studies were assessed for quality using the Cochrane Collaboration Risk of Bias assessment tool,and valid data were extracted and meta-analyzed using RevMan5.4 software.Results A total of 184 articles were screened and 4 Chinese RCTs were finally included,with a sample size of 267 cases.Meta-analysis showed that the overall efficacy of combination therapy for MDRAB/XDRAB CNS infection was better than monotherapy[OR = 4.30,95%CI =(1.93,9.58),P＜0.01].Combination therapy had a better bacterial clearance[OR=4.20,95%CI=(2.08,8.48),P＜0.01].And combination therapy resulted in a lower incidence of adverse effects[OR= 0.19,95%CI =(0.05,0.67),P＜0.05].There was no apparent difference in cure rate between combination therapy and monotherapy(P＞0.05).Conclusion Current evidence suggests that tigecycline combined with cefoperazone-sulbactam sodium may have better clinical efficacy and safety than monotherapy for MDRAB/XDRAB CNS infections.Limited by the number and quality of included studies,needs to be verified by more and higher-quality studies.
